0001578563-21-000036.txt : 20211007 0001578563-21-000036.hdr.sgml : 20211007 20211007211800 ACCESSION NUMBER: 0001578563-21-000036 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211007 FILED AS OF DATE: 20211007 DATE AS OF CHANGE: 20211007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAYER AKTIENGESELLSCHAFT CENTRAL INDEX KEY: 0001144145 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 211313685 BUSINESS ADDRESS: STREET 1: BAYERWERK, GEBAEUDE W11 STREET 2: KAISER-WILHELM-ALLEE CITY: LEVERKUSEN STATE: 2M ZIP: D-51368 BUSINESS PHONE: 492143081933 MAIL ADDRESS: STREET 1: BAYERWERK, GEBAEUDE W11 STREET 2: KAISER-WILHELM-ALLEE CITY: LEVERKUSEN STATE: 2M ZIP: D-51368 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bayer World Investments B.V. CENTRAL INDEX KEY: 0001820027 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 211313686 BUSINESS ADDRESS: STREET 1: ENERGIEWEG 1 CITY: MIJDRECHT STATE: P7 ZIP: 3641 BUSINESS PHONE: 00 31 297 280 666 MAIL ADDRESS: STREET 1: ENERGIEWEG 1 CITY: MIJDRECHT STATE: P7 ZIP: 3641 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: SUITE 1555 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: (617) 351-2575 MAIL ADDRESS: STREET 1: 800 BOYLSTON STREET STREET 2: SUITE 1555 CITY: BOSTON STATE: MA ZIP: 02199 3 1 primary_doc.xml PRIMARY DOCUMENT X0206 3 2021-10-07 0 0001782223 Pyxis Oncology, Inc. PYXO 0001820027 Bayer World Investments B.V. ENERGIEWEG 1 MIJDRECHT P7 3641RT NETHERLANDS 0 0 1 0 0001144145 BAYER AKTIENGESELLSCHAFT BAYERWERK, GEBAEUDE W11 KAISER-WILHELM-ALLEE 1 LEVERKUSEN 2M 51373 GERMANY 0 0 1 0 Series A Convertible Preferred Stock Common Stock 1786831 D Series B Convertible Preferred Stock Common Stock 955507 D Shares of Series A and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") have no expiration date and, as of the date of this filing, are convertible, at the option of the Reporting Persons, into shares of the Issuer's common stock at a 6.359-for-1 conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares). Reflects that each 6.359 shares of Preferred Stock will convert automatically into one share of the Issuer's common stock at the closing of the Issuer's initial public offering, for no additional consideration (subject to the payment of cash in lieu of any fractional shares). The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Bayer World Investments B.V., By: /s/ Patrick Lennaerts, Name: Patrick Lennaerts, Title: Managing Director 2021-10-07 Bayer Aktiengesellschaft, By: /s/ Christian Bank, Name: Christian Bank, Title: Head of Legal Mergers & Acquisitions 2021-10-07